TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
ATE262520T1
(de)
*
|
1998-06-16 |
2004-04-15 |
Sod Conseils Rech Applic |
Imidazol-derivate
|
SK284723B6
(sk)
|
1998-07-06 |
2005-10-06 |
Janssen Pharmaceutica N. V. |
Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti
|
PT1094815E
(pt)
*
|
1998-07-06 |
2004-04-30 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para tratamento de artropatias
|
CA2341739C
(en)
*
|
1998-08-27 |
2005-07-12 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
WO2000034239A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
KR100712226B1
(ko)
|
1998-12-23 |
2007-04-27 |
얀센 파마슈티카 엔.브이. |
1,2-어닐링된 퀴놀린 유도체
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(en)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazolyl derivatives
|
JP4883862B2
(ja)
|
1999-11-15 |
2012-02-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼ阻害剤としてのトリアゾール類
|
EP1106612B1
(en)
*
|
1999-11-30 |
2004-02-11 |
Pfizer Products Inc. |
Quinoline derivatives useful for inhibiting farnesyl protein transferase
|
KR20010077400A
(ko)
*
|
2000-02-02 |
2001-08-17 |
성재갑 |
에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
|
PT1255537E
(pt)
*
|
2000-02-04 |
2006-09-29 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para tratar cancro da mama
|
CA2397558A1
(en)
|
2000-02-24 |
2001-08-30 |
Janssen Pharmaceutica N.V. |
Dosing regimen
|
EP1261374A2
(en)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
AU2001254672A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
EP1267871A2
(en)
*
|
2000-02-29 |
2003-01-02 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
AU2001235496A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
|
US20030027808A1
(en)
*
|
2000-02-29 |
2003-02-06 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with platinum compounds
|
CA2397694A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Farnesyl protein transferase inhibitor combinations
|
EP1261341A2
(en)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with camptothecin compounds
|
JP2003525237A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
AU2001256166A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
|
JP2003525239A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
CA2397475A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with vinca alkaloids
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
EP1319661B1
(en)
*
|
2000-09-21 |
2006-03-01 |
Takeda Pharmaceutical Company Limited |
Process for producing a tricyclic fused heterocyclic derivative
|
US7173040B2
(en)
|
2000-09-25 |
2007-02-06 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
|
AU2002220559A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
EP1322635B1
(en)
|
2000-09-25 |
2006-03-22 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
US7067531B2
(en)
|
2000-09-25 |
2006-06-27 |
Angibaud Patrick Rene |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
US7153958B2
(en)
|
2000-11-21 |
2006-12-26 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting benzoheterocyclic derivatives
|
EP1339407B1
(en)
*
|
2000-11-28 |
2006-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
|
WO2002051835A1
(en)
|
2000-12-27 |
2002-07-04 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
JP4969016B2
(ja)
*
|
2001-02-15 |
2012-07-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
|
PL208238B1
(pl)
|
2001-03-12 |
2011-04-29 |
Janssen Pharmaceutica Nv |
Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
|
ATE425978T1
(de)
*
|
2001-12-19 |
2009-04-15 |
Janssen Pharmaceutica Nv |
Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
|
WO2003080058A1
(en)
|
2002-03-22 |
2003-10-02 |
Janssen Pharmaceutica. N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
JP4384505B2
(ja)
*
|
2002-04-15 |
2009-12-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
WO2004022097A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
AU2004229501B2
(en)
|
2003-04-11 |
2011-08-18 |
Medimmune, Llc |
Recombinant IL-9 antibodies and uses thereof
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US20050048617A1
(en)
|
2003-08-18 |
2005-03-03 |
Medimmune, Inc. |
Humanization of antibodies
|
FR2860235A1
(fr)
*
|
2003-09-29 |
2005-04-01 |
Yang Ji Chemical Company Ltd |
Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
CA2559282A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
DK2362218T3
(en)
|
2004-11-05 |
2014-11-17 |
Janssen Pharmaceutica Nv |
Methods for monitoring the effectiveness of farnesyl transferase
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007075923A2
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
EP2016070B1
(en)
|
2006-04-20 |
2016-01-13 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
KR101367645B1
(ko)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
C-fms 키나제의 저해제로서의 복소환식 화합물
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
WO2009058379A2
(en)
|
2007-10-31 |
2009-05-07 |
Medimmune, Llc |
Protein scaffolds
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
BRPI0920927A2
(pt)
*
|
2008-11-13 |
2019-09-24 |
Link Medicine Corp |
derivados de azaquinolinona e usos dos mesmos
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
IN2012DN03312A
(xx)
*
|
2009-10-22 |
2015-10-23 |
Fibrotech Therapeutics Pty Ltd |
|
US8541404B2
(en)
*
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
CN106244707A
(zh)
|
2010-07-28 |
2016-12-21 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
US9334332B2
(en)
|
2012-07-25 |
2016-05-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
EP2906661B1
(de)
*
|
2012-10-11 |
2016-10-26 |
Merck Patent GmbH |
Materialien für organische elektrolumineszenzvorrichtungen
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
CN105764526B
(zh)
|
2013-08-26 |
2020-12-15 |
生物技术研发公司 |
编码抗唾液酸化路易斯a抗原的人抗体的核酸
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015271685B2
(en)
|
2014-06-04 |
2021-02-18 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
SG11201704752WA
(en)
|
2014-12-11 |
2017-07-28 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
PT3265123T
(pt)
|
2015-03-03 |
2023-02-01 |
Kymab Ltd |
Anticorpos, usos e métodos
|
ES2901506T3
(es)
|
2015-08-17 |
2022-03-22 |
Kura Oncology Inc |
Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
PT3534885T
(pt)
|
2016-11-03 |
2021-04-13 |
Kura Oncology Inc |
Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JP2020522512A
(ja)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
WO2018222689A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|